BrainStorm Cell Therapeutics Inc. (BCLI) stock
BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.01 (-1.17%)
Close on Oct 19, 2026Market cap $8.50MP/E –Yield –
BrainStorm Cell Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
BrainStorm Cell Therapeutics's total debt was $1.26M at Jun 30, 2026. For fiscal 2025 it was $967.00K, up 222.3% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $967.00K | +222.3% |
| FY2024 | Dec 31, 2024 | $300.00K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.26M | +1148.5% |
| Q1 FY2026 | Mar 31, 2026 | $1.33M | +10.7% |
| Q4 FY2025 | Dec 31, 2025 | $967.00K | +222.3% |
| Q3 FY2025 | Sep 30, 2025 | $101.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $101.00K | – |
| Q1 FY2025 | Mar 31, 2025 | $1.20M | – |
| Q4 FY2024 | Dec 31, 2024 | $300.00K | – |
See a number that looks wrong?